Nuochengjianhua announced that zoletrinib, a new-generation TRK inhibitor independently developed by the company, is used to treat adults carrying the NTRK fusion gene and young people with solid tumors over the age of 12, making it the first self-developed next-generation TRK inhibitor approved for marketing. In key registered clinical trials, zoletriptinib showed an overall remission rate of 89.1%, a disease control rate of 96.4%, a 24-month progression-free survival rate of 77.4%, and a 24-month overall survival rate of 90.8%.

Nuochengjianhua announced that zoletrinib, a new-generation TRK inhibitor independently developed by the company, is used to treat adults carrying the NTRK fusion gene and young people with solid tumors over the age of 12, making it the first self-developed next-generation TRK inhibitor approved for marketing. In key registered clinical trials, zoletriptinib showed an overall remission rate of 89.1%, a disease control rate of 96.4%, a 24-month progression-free survival rate of 77.4%, and a 24-month overall survival rate of 90.8%.